Drug intelligence / Profile preview

anti-hOX40 antibody 1

Development stage
Preclinical
Lead developer
Shanghai Model Organisms Center
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intraperitoneal
01

Overview

anti-hOX40 antibody 1 is a human-specific agonistic monoclonal antibody targeting OX40 (CD134), a member of the tumor necrosis factor receptor superfamily (TNFRSF4). OX40 is primarily expressed on activated T cells, and its activation provides a potent costimulatory signal that enhances effector T cell proliferation, survival, and cytokine production while potentially suppressing regulatory T cell (Treg) activity. In preclinical research presented at AACR 2024, this antibody (referred to as Ab1) demonstrated dose-dependent anti-tumor efficacy in humanized OX40 knock-in mouse models, particularly in syngeneic MC38 tumor models. The study evaluated its performance as a monotherapy and in combination with PD-1 inhibitors to determine optimal dosing sequences for immunotherapy regimens.

Other names
anti-human OX40 agonist Ab1
02

Targets

TNFRSF4 (OX40 receptor)CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on anti-hOX40 antibody 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-hOX40 antibody 1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call